Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $795

Benzinga · 3d ago
Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $750 to $795.